Potential Markers in Cardiac Hypertrophy?

Cardiomyopathies are diagnosed based on medical history of patient (symptoms and family history), physical examination, results of echocardiogram and in some situations additionally ECG or chest-X-ray results. Currently used non-invasive diagnostic methods, could be complemented by biochemical tests. In this review some emerging potential biomarkers such as: osteopontin, ST-2 receptor, osteoprotegerin, neopterin, urocortins, growth differentiation factor 15 and urotensin II are described. In current article human and non human investigations have been reviewed, since rat is most commonly used model in experimental cardiology and gives important foundations to clinical knowledge.

• Publication year

  2012

• Venue

  EJIFCC

• Publication date

  2012-07-01

• Fields of study

  Medicine

• Identifiers
  PMID 27683411PMCID 4975242
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Left Ventricular Hypertrophy

  2020cited by this paper
• Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update

  2011cited by this paper
• Growth differentiation factor 15 deficiency protects against atherosclerosis by attenuating CCR2-mediated macrophage chemotaxis

  2011cited by this paper
• 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2011cited by this paper
• Osteopontin: role in immune regulation and stress responses.

  2011cited by this paper
• Neurohumoral and inflammatory markers for prediction of right ventricular failure after implantation of a left ventricular assist device

  2011cited by this paper
• The counter-regulation of atherogenesis: a role for interleukin-33.

  2010cited by this paper
• Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension‐induced left ventricular hypertrophy and heart failure

  2010cited by this paper
• Prognostic value of osteoprotegerin in chronic heart failure: The GISSI-HF trial.

  2010cited by this paper
• ST2: A Novel Remodeling Biomarker in Acute and Chronic Heart Failure

  2010cited by this paper
• Urotensin II Induces Rat Cardiomyocyte Hypertrophy via the Transient Oxidization of Src Homology 2-Containing Tyrosine Phosphatase and Transactivation of Epidermal Growth Factor Receptor

  2009cited by this paper
• Therapeutic implications of osteoprotegerin

  2009cited by this paper
• Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.

  2009cited by this paper
• Perusal of risk stratification of acute myocardial infarction for half a century.

  2009cited by this paper
• [Postinfarction cardiac remodeling--clinical consequences].

  2009cited by this paper
• Osteopontin, a New Prognostic Biomarker in Patients With Chronic Heart Failure

  2008cited by this paper
• Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.

  2008cited by this paper
• Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction

  2008cited by this paper
• Dilated cardiomyopathy: a review

  2008cited by this paper
• IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system.

  2007cited by this paper
• Osteopontin and cardiovascular system

  2007cited by this paper
• [Cytokines, metalloproteinases, neopterin and cardiovascular mortality among patients with chronic renal failure].

  2007cited by this paper
• Detection of neopterin as parameter of potential monocyte activation in patients with acute ischemic stroke.

  2007cited by this paper
• IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines.

  2005cited by this paper
• Regeneration of Infarcted Myocardium by Intramyocardial Implantation of Ex Vivo Transforming Growth Factor-&bgr;–Preprogrammed Bone Marrow Stem Cells

  2005cited by this paper
• Genes for left ventricular hypertrophy

  2004cited by this paper
• Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases.

  2004cited by this paper
• Inhibition of TGF-beta signaling exacerbates early cardiac dysfunction but prevents late remodeling after infarction.

  2004cited by this paper
• Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction.

  2004cited by this paper
• Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction

  2004cited by this paper
• Osteopontin modulates angiotensin II-induced fibrosis in the intact murine heart.

  2004influential reference
• Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases

  2003cited by this paper
• Physiological antagonism of angiotensin II and lipopolysaccharides in early endotoxemia: pharmacometric analysis.

  2003cited by this paper
• Expression and Regulation of ST2, an Interleukin-1 Receptor Family Member, in Cardiomyocytes and Myocardial Infarction

  2002cited by this paper
• Transforming Growth Factor-β Function Blocking Prevents Myocardial Fibrosis and Diastolic Dysfunction in Pressure-Overloaded Rats

  2002cited by this paper
• RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function.

  2002cited by this paper
• Hypertrophic cardiomyopathy: a systematic review.

  2002cited by this paper
• Expression and Regulation of ST 2 , an Interleukin-1 Receptor Family Member , in Cardiomyocytes and Myocardial Infarction

  2002cited by this paper
• Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats.

  2001cited by this paper
• Bone Morphogenetic Protein-2 Inhibits Serum Deprivation-induced Apoptosis of Neonatal Cardiac Myocytes through Activation of the Smad1 Pathway*

  2001cited by this paper
• Increased plasma adhesion molecule levels in patients with heart failure who have ischemic heart disease and dilated cardiomyopathy.

  2001cited by this paper
• Increased serum neopterin: a marker of coronary artery disease activity in women

  2000cited by this paper
• Role of transforming growth factor beta in human disease.

  2000cited by this paper
• Left ventricular hypertrophy: pathogenesis, detection, and prognosis.

  2000cited by this paper
• Characterization of Growth-Differentiation Factor 15, a Transforming Growth Factor β Superfamily Member Induced following Liver Injury

  2000cited by this paper
• Expression of a novel member of the TGF-β superfamily, growth/differentiation factor-15/macrophage-inhibiting cytokine-1 (GDF-15/MIC-1) in adult rat tissues

  1999cited by this paper
• Molecular mechanisms of myocardial remodeling.

  1999cited by this paper
• MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily.

  1997cited by this paper
• Myocardial osteopontin expression is associated with left ventricular hypertrophy.

  1997cited by this paper
• Osteopontin is produced by rat cardiac fibroblasts and mediates A(II)-induced DNA synthesis and collagen gel contraction.

  1996cited by this paper
• Studies on Natural ST2 Gene Products in the Human Leukemic Cell Line UT-7 Using Monoclonal Antihuman ST2 Antibodies

  1995cited by this paper
• Hypertrophic cardiomyopathy.

  1994cited by this paper
• Transforming growth factor beta in tissue fibrosis.

  1994cited by this paper
• Mediation of cardioprotection by transforming growth factor-beta.

  1990cited by this paper
• Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.

  1986cited by this paper
• The Law of Laplace: Its Limitations as a Relation for Diastolic Pressure, Volume, or Wall Stress of the Left Ventricle

  1980cited by this paper
• Human Neuroscience Hypothesis and Theory Article Attentional Switching in Humans and Flies: Rivalry in Large and Miniature Brains

  year unknowncited by this paper

• Catalase Mediates the Inhibitory Actions of PPARδ against Angiotensin II-Triggered Hypertrophy in H9c2 Cardiomyocytes

  2021cites this paper
• Cafestol Activates Nuclear Factor Erythroid-2 Related Factor 2 and Inhibits Urotensin II-Induced Cardiomyocyte Hypertrophy.

  2019cites this paper
• Biomarcadores de Hipertrofia Ventricular Esquerda em doentes com Hipertensão Arterial

  2019cites this paper
• Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac hypertrophy in cell models

  2018cites this paper
• Biomarkers Beyond the Natriuretic Peptides for Chronic Heart Failure: Galectin-3 and Soluble ST2

  2012cites this paper
• THE NATRIURETIC PEPTIDES FOR CHRONIC HEART FAILURE : GALECTIN-3 AND SOLUBLE ST 2

  2012cites this paper
• Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac Ubiquitin-protein ligase E3a (UBE3A) as a new biomarker of cardiac hypertrophy in cell

  year unknowncites this paper